INIFY Laboratories AB

As of June 30, 2026, INIFY Laboratories AB carries a market capitalization of 827.61M, placing it among publicly traded companies globally. Its enterprise value stands at 735.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, INIFY Laboratories AB has 107.47M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 26.23, and the price-to-book ratio stands at 5.08.

These figures are as of June 30, 2026. The EV/Sales ratio of 30.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 735.12M versus a market cap of 827.61M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, INIFY Laboratories AB maintains a current ratio of 6.90, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, INIFY Laboratories AB posted a negative return on equity (ROE) of -52.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -47.36, reflecting losses generated across the asset base. The company generates approximately 688,608.54 in revenue per employee across its workforce of 35.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.38 indicates how many times INIFY Laboratories AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 19, 2026, INIFY Laboratories AB's stock has declined approximately 4.88% over the past 52 weeks. The 50-day moving average sits at 6.80, while the 200-day moving average is 5.29.

Over the twelve months ended June 30, 2026, INIFY Laboratories AB generated 24.10M in revenue and converted that into -80.21M in net income, yielding earnings per share of -0.98. EBITDA reached -71.33M, while operating income came in at -81.69M.

These figures are as of June 30, 2026. Total book value stands at 162.92M, with working capital of 88.26M providing operational flexibility.

Over the twelve months ended June 30, 2026, INIFY Laboratories AB posted a gross margin of 85.10, reflecting its pricing power and cost economics. The operating margin of -338.96 and net profit margin of -332.81 provide insight into operational efficiency.

INIFY Laboratories AB's most recent stock split took place on December 16, 2024.